Rapid FilmArray Blood Culture Identification Panel (BCID) Testing
Prompt initiation of appropriate antimicrobial therapy is associated with improved outcomes. Definitive identification of the causative organism through traditional culture methods often requires 24–72 hours. This delay can lead to administration of either inadequate or overly broad antimicrobial therapy. Inappropriate antimicrobial selection may result in therapy-related complications, suboptimal patient outcomes, emergence of antimicrobial resistance, and excessive healthcare costs. BCID is a test capable of accurately identifying approximately 85-90% of bloodstream pathogens in positive-blood cultures within 1 hour. As such, BCID testing may significantly reduce the time to reporting of culture results by up to 48 hours compared to conventional methods and provide more timely and accurate information to clinicians. It is uncertain whether BCID testing coupled with an existing ASP may provide incremental benefit for patients.
Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive care medicine. 2001;27 Suppl 1:S33-48.
Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;51(9):1074-80.